IASLC World Conference on Lung Cancer

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

T. Jeroen N. Hiltermann, MD, discusses findings from phase 1/2 ARTEMIDE-01 trial.

By Ariana Pelosci

T-DXd Displays Clinical Benefit in HER2-Overexpressed Metastatic NSCLC

Patients with EGFR-mutated NSCLC demonstrated reduced symptom progression when treated with amivantamab plus lazertinib vs osimertinib.

Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

T-DXd showed clinical activity regarding responses and survival outcomes in patients with pretreated HER2-overexpressed metastatic non–small cell lung cancer.

Benjamin Besse, MD, PhD, of Institute Gustave Roussy

By Benjamin Besse, MD

Tusamitamab Ravtansine Misses Survival End Points in Advanced NSCLC Trial

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Benjamin Besse, MD, PhD, a medical oncologist and professor of medicine at Paris Saclay University, Institut Gustave Roussy, Villejuif, France

Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure

Tusamitamab ravtansine vs docetaxel was not significantly different regarding survival in patients with advanced nonsquamous non–small cell lung cancer.

By Courtney Flaherty

Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC

Taletrectinib was safe and generated durable responses in both TKI-naive and -pretreated patients with ROS1-positive non–small cell lung cancer.

By Gina Mauro

Dr Le on SOHO-01 Data With BAY 2927088 in HER2-Mutated NSCLC

Neoadjuvant durvalumab plus chemotherapy and adjuvant durvalumab improves event-free survival in stage IIA-IIIB resectable non–small cell lung cancer vs. placebo.

Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center

By Xiuning Le, MD, PhD

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC

Xiuning Le, MD, PhD, discusses updated findings from the phase 1/2 SOHO-01 trial.

Hidehito Horinouchi, MD, PhD, medical oncologist, Department of Thoracic Oncology, National Cancer Center Hospital

Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC

The safety profile of adjuvant alectinib was tolerable and manageable in ALK-positive NSCLC.

By Ryan Scott

Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status

Tarlatamab demonstrated durable responses and long-term tolerability in patients with previously treated small cell lung cancer.

By Kristi Rosa

Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLC

Rilvegostomig induced responses with acceptable tolerability in patients with checkpoint inhibitor-naive, metastatic NSCLC.

Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre

By Natasha B Leighl, MD, BSc, MMSc

Dr Heymach on Updated AEGEAN Data in Resectable NSCLC

Natasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.

John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center

By John Heymach, MD, PhD

Analysis Further Shows Perioperative Pembrolizumab Efficacy in Early-Stage NSCLC

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.

By Jason Broderick

Osimertinib Plus Savolitinib Exhibits Clinically Meaningful ORR vs Osimertinib in EGFR+ NSCLC

Neoadjuvant pembrolizumab plus chemotherapy led to greater pathologic regression vs placebo plus chemotherapy in early-stage non–small cell lung cancer.

Lung Cancer | Image Credit: © Axel Kock - stock.adobe.com

Firmonertinib Shows Antitumor Activity in EGFR PACC-Mutated NSCLC

The combination of osimertinib/savolitinib demonstrated a significant improvement in ORR in de novo MET-aberrant, EGFR-mutant advanced NSCLC.

By Dylann Cohn-Emery

Aumolertinib Improves PFS in Unresectable, Stage III EGFR+ NSCLC after Chemoradiotherapy

Treatment with firmonertinib was safe and effective for patients with EGFR P-loop and αC-helix compressing-mutated non–small cell lung cancer.

Aumolertinib in non–small cell lung cancer

By Chris Ryan

Zongertinib Demonstrates Clinically Meaningful Efficacy in HER2-Mutated NSCLC

Treatment with aumolertinib led to an improvement in progression-free survival in unresectable, stage III, EGFR-mutated non–small cell lung cancer.

By Russ Conroy

BAY 2927088 Displays Durable Responses in HER2-Mutated NSCLC

Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated non–small cell lung cancer.

By Ariana Pelosci

Sacituzumab Govitecan Generates Responses With Manageable Safety Profile in ES-SCLC

BAY 2927088 demonstrated durable response rates for patients with pretreated HER2-mutant non–small cell lung cancer.

By Ashling Wahner

Dr Wu on SAFFRON-301 Data in Advanced or Metastatic NSCLC

Treatment with sacituzumab govitecan in the second-line setting yielded antitumor activity in patients with extensive-stage small cell lung cancer.

Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University

By Yi-Long Wu, MD, PhD

Dato-DXd Misses OS End Point in TROPION-Lung01 Study for NSCLC

Yi-Long Wu, MD, PhD, discusses findings from the phase 3 SAFFRON-301 trial in patients with advanced or metastatic NSCLC.

Jacob Sands, MD, of Dana-Farber Cancer Institute

By Silas Inman

HS-20093 Generates Responses in Pretreated ES-SCLC

Dato-DXd did not significantly improve overall survival compared with docetaxel for patients with non–small cell lung cancer.

By Chris Ryan

Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC

HS-20093 produced responses in extensive-stage small cell lung cancer after prior platinum-based chemotherapy with or without prior immunotherapy.

TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC

When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.

Marina Chiara Garassino, MD, from the University of Chicago

By Silas Inman

Dr Sen on Interim IDeate-Lung01 Data in Extensive-Stage SCLC

An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with non–small cell lung cancer treated with datopotamab deruxtecan.

Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai

By Triparna Sen, PhD

Patient-Level Data Support Perioperative Nivolumab Use in Resectable NSCLC

Triparna Sen, PhD, discusses findings from an interim analysis of the phase 2 IDeate-Lung01 trial in patients with extensive-stage small cell lung cancer.

Patrick Forde, MBBCH, of Johns Hopkins Medicine

Novel Perioperative Combinations Show Efficacy in Resectable NSCLC

Event-free survival improved with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy in resectable NSCLC, according to a comparison of 2 trials.

Tina Cascone, MD, PhD, of MD Anderson Cancer Center

By Megan Hollasch